Humedix recruits R&D and clinical expert, appoints Choi Seung-in as new Head of R&D Division

[Financial News] Humedix, part of Huons Group, has appointed a new Head of R&D Division to strengthen its research and development capabilities and secure future growth engines.
Humedix announced on the 9th that it has named Executive Director Choi Seung-in as its new Head of R&D Division (photo).
Choi, the new R&D chief, graduated from the Department of Chemical Engineering at Myongji University and went on to earn a master’s degree in biochemical engineering and a Ph.D. in life sciences from the same graduate school. He has served as head of the research planning team at AHN-GOOK PHARMACEUTICAL, senior researcher at Quegen Biotech, and head of the research institute at Genewel. Most recently, he worked as Head of R&D Division at BioPlus, where he oversaw the entire cycle from new product research and development to clinical stages for pharmaceuticals and medical devices, including combination therapies for anticancer drugs and sepsis, hyaluronic acid fillers, wound dressings, adhesion barriers, and diabetes treatments.
Going forward, Choi will oversee all R&D activities at Humedix, including pharmaceuticals and medical devices.
“I am pleased to join Humedix, one of Korea’s leading aesthetic specialists, as head of R&D,” said Choi Seung-in. “Drawing on more than 20 years of knowledge and experience in the pharmaceutical and biotech field, I will work to develop products that can lead the global aesthetic market.”

wonder@fnnews.com Jung Sang-hee Reporter